Risk of Pleural Effusion in Multiple Myeloma
Pleural effusion occurs in approximately 42.7% of multiple myeloma patients and indicates a poor prognosis, with median overall survival of only 13 months when the effusion is myelomatous (directly caused by myeloma cells), compared to 60.6 months in patients without pleural effusion 1, 2.
Incidence and Types
Pleural effusion in multiple myeloma falls into two distinct categories:
Non-myelomatous pleural effusion (most common): Occurs in 6-14% of MM patients and results from secondary causes including congestive heart failure, renal failure, hypoalbuminemia, pneumonia, pulmonary infarction, and amyloidosis 3, 4
Myelomatous pleural effusion (MPE): Extremely rare (<1% of MM patients), caused by direct myeloma cell infiltration of the pleura, and represents a form of extramedullary disease 3, 4, 5
The higher 42.7% incidence reported in the most recent real-world study 1 likely reflects all causes of pleural effusion, not just myelomatous effusion, and suggests this complication is more common in clinical practice than previously recognized.
Clinical Characteristics
Patients with pleural effusion typically present with:
- Small, bilateral effusions in most cases 1
- Median time from MM diagnosis to pleural effusion development: 6.8 months (range 0.8-33.6 months) 1
- Can occur in all MM subtypes 1
- Yellow exudative fluid when myelomatous 4
- Yellow nodules on pleura with abundant blood supply (in MPE cases) 4
Myelomatous pleural effusion specifically shows:
- Higher β2-microglobulin levels 2
- Greater prevalence of multisite extramedullary lesions (69.2% vs 38.0%) 2
- Higher International Staging System stage III disease (76.9% vs 44.8%) 2
Risk Factors
At initial MM diagnosis, risk factors for pleural effusion include:
- High plasma cell proportion (OR 1.373,95% CI 1.153-1.634) 1
- Amyloidosis (OR 1.791,95% CI 1.408-2.279) 1
At MM relapse, risk factors include:
- High plasma cell proportion (OR 1.853,95% CI 1.451-2.368) 1
- Pneumonia (OR 1.309,95% CI 1.143-1.498) 1
- Heart failure (OR 1.815,95% CI 1.387-2.374) 1
Prognostic Impact
The presence of pleural effusion dramatically worsens survival:
- Patients with any pleural effusion: HR 2.249 (95% CI 1.774-2.852) for death compared to those without 1
- Critical finding: Even small pleural effusions carry the same poor prognosis as moderate to large effusions (HR 1.402,95% CI 1.037-1.896, not statistically different) 1
- Myelomatous pleural effusion: Median OS only 13 months vs 37 months for other extramedullary disease 2
- MPE is an independent prognostic indicator (HR 2.669,95% CI 1.132-6.293) 2
Diagnostic Approach
To distinguish myelomatous from non-myelomatous pleural effusion:
Exclude secondary causes first: Evaluate for heart failure, renal failure, hypoalbuminemia, pneumonia, pulmonary embolism, and amyloidosis 3, 4
Routine cytology has low sensitivity - standard pathological examination often misses myeloma cells 4
Flow cytometry is essential for detecting clonal plasma cells in pleural fluid and confirming MPE 4, 6
Cell block preparation with immunohistochemistry improves diagnostic yield 6
Look for typical plasma cell features: eccentric nuclei, amphophilic cytoplasm with paranuclear hof 6
Clinical Pitfalls
- Do not dismiss small pleural effusions - they carry the same poor prognosis as larger effusions 1
- Do not rely solely on routine cytology - flow cytometry is necessary to exclude MPE 4
- MPE at initial presentation is exceptionally rare but represents an ominous sign with survival measured in months 5, 6
- The detection rate of MPE is very low even when present, requiring high clinical suspicion and appropriate testing 4
Management Implications
While the provided guidelines 7, 8 do not specifically address pleural effusion management in MM, the evidence clearly shows that pleural effusion warrants aggressive treatment of the underlying myeloma and consideration of the patient as high-risk. When MPE is confirmed, median survival is approximately 4 months despite treatment 9, making this a terminal complication requiring palliative care discussions alongside aggressive chemotherapy.